newsfilter
← Latest News
Business Wire·

Rocket Pharmaceuticals Reports Third Quarter 2026 Financial Results and Highlights Recent Progress

RCKT
  • FDA alignment established a path to complete the pivotal Phase 2 trial of RP-A501 in Danon disease, with dosing expected to finish by mid-2027.
  • Initial safety observations were encouraging for the first three patients treated under the modified pivotal protocol for RP-A501.
  • Dosing initiated in the Phase 1 trial of RP-A701 for BAG3-associated dilated cardiomyopathy (BAG3-DCM).
  • European Commission granted orphan designation to RP-A701 on October 20, 2026.
  • KRESLADI achieved commercial readiness on October 1, 2026, with two Qualified Treatment Centers activated.
  • Rocket secured a credit facility with Hercules Capital for up to $150 million, receiving an initial $35 million draw.
  • Cash, cash equivalents, and investments totaled $279.4 million as of September 30, 2026, expected to fund operations into Q3 2028.
  • Research and development expenses were $31.2 million for the quarter ended September 30, 2026, a decrease from the prior year.
  • General and administrative expenses increased to $19.8 million for the quarter ended September 30, 2026.
  • The company reported a net loss of $49.2 million, or $0.43 per share, for the three months ended September 30, 2026.
  • Approximately 111.4 million shares of common stock were outstanding as of September 30, 2026.
  • Rocket estimates 10,000-11,000 people live with Danon disease in the U.S., having identified over 900 patients.
  • Continued advancement of RP-A601 in PKP2-ACM includes ongoing Phase 1 enrollment and FDA engagement for a potential pivotal study.
  • KRESLADI is an autologous gene therapy for severe leukocyte adhesion deficiency-I (LAD-I) administered as a one-time infusion.
  • Safety warnings for KRESLADI include risks of serious infections, veno-occlusive disease, neutrophil engraftment failure, \& hematologic malignancy.